medigraphic.com
ISSN 1729-519X (Print)

2021, Number 1

<< Back Next >>

Revista Habanera de Ciencias Médicas 2021; 20 (1)

Amotivational syndrome in chronic marijuana users. A narrative review to approach the concept

Castaño PGA, Becoña IE, Scoppetta DGO, Restrepo ESM

Language: Spanish
References: 50
Page: 1-16
PDF size: 829.53 Kb.


ABSTRACT

Introduction: Over the past sixty years, evidence for the adverse effects of chronic cannabis use has been demonstrated. Memory and concentration problems, the risk of schizophrenia in predisposed subjects, and amotivational syndrome have been referenced. There is not much doubt in relation to the first effect mentioned, but there is controversy around the last.
Objective: To review the existing scientific evidence for the amotivational syndrome.
Material and Methods: The review was conducted through academic database searching. The publications related to mental disorders associated with the chronic marijuana use, which referred to amotivational syndrome that fulfilled the criteria for articles attached to international standards, were taken into account.
Results: A total of 31 articles were included. Of them, 16 presented the definition of amotivational syndrome. Once all the sources were integrated, the evidence found in 15 factors was organized. These factors included: apathy; disinterest; passivity; indifference; delay to perform tasks; sloth; presentism; reluctance to do prolonged activities that require attention or tenacity; abandonment of personal care; sexual disinterest; decreased reflexes; decreased self-efficacy; impairment in communication skills; social withdrawal, and unaltered affection.
Conclusions: Based on these findings, we suggest that the amotivational syndrome is a constellation of symptoms and / or related signs which could constitute a typical morbidity caused by chronic cannabis use, so we expect that future research will be developed to demonstrate or discard their existence.


REFERENCES

  1. Budney AJ, Borodovky JT, Knapp AA. Clinical manifestations of Cannabis use disorder. En su: Cannabis use Disorders. New York: Springer; 2019.p. 85-91.

  2. Abarca Villalobos Z, Flores Sandí G. Uso terapéutico de cannabinoides bajo prescripción médica. Acta Médica Costarric. 2007;49(2):114-7.

  3. Ministerio de Salud. La marihuana con uso terapéutico en el contexto colombiano. Gobierno apoya discusión en el congreso sobre uso terapéutico de marihuana [Internet]. Colombia: Ministerio de Salud; 2014 [Citado 25/04/2017]. Disponible en: https://www.minsalud.gov.co/sites/rid/lists/bibliotecadigital/ride/de/marihuana%20con%20uso%20terapeutico-contexto%20colombiano.pdf

  4. Morales Basto JP, Poveda Espinosa E. Efectos del consumo de marihuana en adultos sobre la ingesta y el metabolismo de los nutrientes: una revisión. Revista Española de Nutrición Humana y Dietética. 2017; 21(3): 280-92.

  5. National Institute on Drug Abuse. Abuso de la Marihuana [Internet]. Estados Unidos: National Institute on Drug Abuse; 2013 [Citado 25/04/2017]. Disponible en: https://www.drugabuse.gov/sites/default/files/marihuana_rr_sp_2013.pdf

  6. Tziraki S. Trastornos mentales y afectación neuropsicológica relacionados con el uso crónico de cannabis. Rev Neurol. 2012;54(12):750-60.

  7. Montoya ID, Weiss SRB. Introduction to Cannabis Use Disorders. En su: Cannabis Use Disorders. New york: Springer Springer; 2019. p. 1-6.

  8. Brutlag A, Hommerding H. Toxicology of marijuana, synthetic cannabinoids, and cannabidiol in dogs and cats. Veterinary Clinics: Small Animal Practice. 2018; 48(6): 1087-102.

  9. Granados OS. Exploración psicométrica sobre deficiencia motivacional en consumidores de marihuana. Interdisciplinaria. Revista de Psicología y Ciencias Afines. 2020; 37(1): 34-9.

  10. Köguel CC. Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática. Adicciones. 2018;30(2):140-51.

  11. Smith DE. Acute and chronic toxicity of marijuana. J Psychodel Drug. 1968;2:37-47.

  12. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An Evaluation of the History of a Marijuana Withdrawal Syndrome in a Large Population. Addiction. 1996; 91:1469-78.

  13. Vélez MMS. Trastornos causados por el consumo de sustancias derivadas del cannabis. RECIAMUC. 2019; 3(3): 1486-502.

  14. Rabin RA. Effects of extended cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. Neuropsychopharmacology. 2017; 42(11): 2259-71.

  15. Calderón Peña B. El consumo de cannabis: bases neurológicas y perspectiva sociológica [Tesis de Especialidad Enfermería]. España: Universidad de Cantabria; 2017 [Citado 25/04/2017]. Disponible en: https://repositorio.unican.es/xmlui/handle/10902/15372

  16. Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy & Behavior. 2017; 70: 292-7.

  17. McGlothlin WH, West LJ. The marihuana problem: an overview. Am J Psychiatry. 1968;125(3):126-34.

  18. Blomfield MAP. The effects of? 9-tetrahydrocannabinol on the dopamine system. Nature. 2016; 539(7629): 369-77.

  19. Manzanares J, Urigüen L, Rubio G, Palomo T. Role of endocannabinoid system in mental diseases. Neurotox Res. 2004;6(3):213-24.

  20. Beeder AB, Millman RB. Treatment of patients with psychopathology and substance abuse. En: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: A comprebensive textbook. 3 ed. Baltimore: Williams & Wilkins; 1997. p. 675-90.

  21. Pope HG, Yurgelun Todd D. The Residual Cognitive Effects of Heavy Marijuana Use in College Students. JAMA [Internet]. 1996 Feb [Citado 25/04/2017];275(7):521-7. Disponible en: http://jamanetwork.com/journals/jama/fullarticle/396766

  22. Scheier LM, Griffin KW. Youth marijuana use: a review of causes and consequences. Current Opinion in Psychology [Internet]. 2020 Jun [Citado 25/04/2017]; 38:11-8. Disponible en: https://europepmc.org/article/med/32653770

  23. Jessor R, Jessor SL, Finney J. Marijuana Use in High School and College. En su: Problem Behavior Theory and Adolescent Health. New York: Springer; 2017. p. 141-60.

  24. Worner CE. Assessing a bystander intervention program for first-year students at the University of Wisconsin-La Crosse [Tesis Doctoral]. Estados Unidos: University of Wisconsin-La Crosse; 2019 [Citado 25/04/2017]. Disponible en: https://minds.wisconsin.edu/handle/1793/79379

  25. Phillips KT, Phillips MM, Lalonde TL, Tormohlen KN. Marijuana use, craving, and academic motivation and performance among college students: An in-the-moment study. Addict Behav. 2015;47:42-7.

  26. Suerken CKl. Marijuana use trajectories and academic outcomes among college students. Drug and Alcohol Dependence. 2016; 162: 137-45.

  27. Lawn W. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational'hypotheses. Psychopharmacology. 2016; 233(20): 3537-52.

  28. Hernandez CM. Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood. Journal of Psychopharmacology [Internet]. 2020 [Citado 25/04/2017];34:[Aprox. 2 p.]. Disponible en: https://doi.org/10.1177/0269881120965931

  29. Barnwell SS, Earleywine M, Wilcox R. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy [Internet]. 2006 [Citado 25/04/2017];1:2. Disponible en: http://dx.doi.org/10.1186/1747-597X-1-2

  30. Petrucci AS, LaFrance EM, Cuttler C. A Comprehensive Examination of the Links between Cannabis Use and Motivation. Substance Use & Misuse. 2020; 55(7): 1155-64.

  31. Lanctôt KL. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimer's & Dementia. 2017;13: 84-100.

  32. Marin N. Apathy: Concept, Syndrome, Neural Mechanisms, and Treatment. Semin Clin Neuropsychiatry. 1996;1(4):304-14.

  33. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147(1):22-30.

  34. Ducharme S, Price BH, Dickerson BC. Apathy: a neurocircuitry model based on frontotemporal dementia. Journal of Neurology Neurosurgery & Psychiatry. 2018;89(4): 389-96.

  35. Perri R. Neuropsychological correlates of cognitive, emotional-affective and auto-activation apathy in Alzheimer's disease. Neuropsychologia. 2018;118: 12-21.

  36. Eslinger PJ, Damasio AR. Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. Neurology. 1985;35(12):1731-41.

  37. Martens KA, Lewis SJG. Pathology of behavior in PD: What is known and what is not?. Journal Neurological Sciences. 2017; 374: 9-16.

  38. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337-43.

  39. Verdejo Garcia A, Benbrook A, Funderburk F, David P, Cadet JL, Bolla KI. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend. 2007;90(1):2-11.

  40. Wylie G. Neuroanatomy: The brain-behavior relationship. En su: Changes in the Brain. New York: Springer. 2017. p. 1-21.

  41. Cummings J. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. Journal Geriatric Psychiatry Neurology. 2015; 28(3): 159-73.

  42. Camargo CHF. Differentiating between apathy and depression in patients with parkinson disease dementia. American Journal of Alzheimer's Disease & Other Dementias. 2018; 33: 30-4.

  43. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry [Internet]. 2001 [Citado 26/04/2017];158(12):2033-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11729021

  44. Chen CY, Wagner FA, Anthony J C. Marijuana use and the risk of Major Depressive Episode. Epidemiological evidence from the United States National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol [Internet]. 2002 [Citado 26/04/2017];37(5):199-206. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12107710

  45. Hanna RC, Pérez JM, Ghose S. Cannabis and development of dual diagnoses: a literature review. The American Journal of Drug and Alcohol Abuse. 2017;43(4): 442-55.

  46. Moore THM, Zammit S, Lingford Hughes A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet [Internet]. 2007 [Citado 26/04/2017];370(9584):319-28. Disponible en: http://thelancet.com/journals/lancet/article/PIIS0140-6736(07)61162-3/abstract

  47. Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci. 1998;10(9):2825-30.

  48. Bechara A. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosci [Internet]. 2005 [Citado 26/04/2017];8(11):1458-63. Disponible en: http://www.nature.com/neuro/journal/v8/n11/full/nn1584.html

  49. Gallego MQ. Cannabis y psicopatología comorbida. Adicciones [Internet]. 2002 [Citado 26/04/2017];14(2):191-200. Disponible en: http://www.adicciones.es/index.php/adicciones/article/view/500

  50. Salgado Carreño AY. Revisión sistemática de los procesos neuropsicológicos afectados en adolescentes y adultos consumidores de marihuana. 2017 [Tesis de Especialidad Psicología]. Colombia: Universidad Cooperativa de Colombia; 2017 [Citado 25/04/2017]. Disponible en: https://repository.ucc.edu.co/handle/20.500.12494/803




2020     |     www.medigraphic.com